These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 34782799)
41. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More. Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C Arch Med Res; 2020 Aug; 51(6):585-586. PubMed ID: 32439198 [TBL] [Abstract][Full Text] [Related]
42. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Jiang Y; Yin W; Xu HE Biochem Biophys Res Commun; 2021 Jan; 538():47-53. PubMed ID: 32943188 [TBL] [Abstract][Full Text] [Related]
43. The Binding of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase May Pave The Way Towards the Design of Potential Drugs for COVID-19 Treatment. Agoni C; Soliman MES Curr Pharm Biotechnol; 2021; 22(11):1520-1537. PubMed ID: 33109039 [TBL] [Abstract][Full Text] [Related]
44. Rapid review for the anti-coronavirus effect of remdesivir. Li Z; Wang X; Cao D; Sun R; Li C; Li G Drug Discov Ther; 2020; 14(2):73-76. PubMed ID: 32378648 [TBL] [Abstract][Full Text] [Related]
45. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model. Chiba S; Kiso M; Nakajima N; Iida S; Maemura T; Kuroda M; Sato Y; Ito M; Okuda M; Yamada S; Iwatsuki-Horimoto K; Watanabe T; Imai M; Armbrust T; Baric RS; Halfmann PJ; Suzuki T; Kawaoka Y mBio; 2021 Feb; 13(1):e0304421. PubMed ID: 35100870 [TBL] [Abstract][Full Text] [Related]
46. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel. Goldberg E; Ben Zvi H; Sheena L; Sofer S; Krause I; Sklan EH; Shlomai A Clin Microbiol Infect; 2021 Jun; 27(6):917.e1-917.e4. PubMed ID: 33705849 [TBL] [Abstract][Full Text] [Related]
47. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117 [TBL] [Abstract][Full Text] [Related]
48. Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review. Qomara WF; Primanissa DN; Amalia SH; Purwadi FV; Zakiyah N Int J Gen Med; 2021; 14():8557-8571. PubMed ID: 34849001 [TBL] [Abstract][Full Text] [Related]
49. Favipiravir and COVID-19: A Simplified Summary. Ghasemnejad-Berenji M; Pashapour S Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367 [TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis. Elsawah HK; Elsokary MA; Abdallah MS; ElShafie AH Rev Med Virol; 2021 Jul; 31(4):e2187. PubMed ID: 33128490 [TBL] [Abstract][Full Text] [Related]
51. On the molecular structure of Remdesivir for the treatment of Covid-19. Sheikholeslami SM; Jahanbani A; Shao Z Comput Methods Biomech Biomed Engin; 2021 Jul; 24(9):995-1002. PubMed ID: 33356621 [TBL] [Abstract][Full Text] [Related]
52. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2. Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821 [TBL] [Abstract][Full Text] [Related]
53. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. Jung LS; Gund TM; Narayan M Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784 [TBL] [Abstract][Full Text] [Related]
54. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience. Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164 [TBL] [Abstract][Full Text] [Related]
55. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. Daou F; Abou-Sleymane G; Badro DA; Khanafer N; Tobaiqy M; Al Faraj A Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33499310 [TBL] [Abstract][Full Text] [Related]
56. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Heyer A; Günther T; Robitaille A; Lütgehetmann M; Addo MM; Jarczak D; Kluge S; Aepfelbacher M; Schulze Zur Wiesch J; Fischer N; Grundhoff A Cell Rep Med; 2022 Sep; 3(9):100735. PubMed ID: 36075217 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. Singh S; Khera D; Chugh A; Khera PS; Chugh VK BMJ Open; 2021 Jun; 11(6):e048416. PubMed ID: 34168031 [TBL] [Abstract][Full Text] [Related]
58. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. Aleissa MM; Silverman EA; Paredes Acosta LM; Nutt CT; Richterman A; Marty FM Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139290 [TBL] [Abstract][Full Text] [Related]
59. Favipiravir in SARS-CoV-2 Infection: Is it Worth it? Batiha GE; Moubarak M; Shaheen HM; Zakariya AM; Usman IM; Rauf A; Adhikari A; Dey A; Alexiou A; Hetta HF; Al-Gareeb AI; Al-Kuraishy HM Comb Chem High Throughput Screen; 2022; 25(14):2413-2428. PubMed ID: 35430987 [TBL] [Abstract][Full Text] [Related]
60. Remdesivir as a broad-spectrum antiviral drug against COVID-19. Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]